Payment overview · 2025
General Payments
$232.32
12 reported records · 8 companies
Healthcare provider profile · identity verified
Dan Thompson, MD
Allopathic & Osteopathic Physicians|Family Medicine · BERNICE, LA · NPI 1205047610
Verified facts
What the public records show
CMS Open Payments records show Dan Thompson, MD received $232.32 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 38.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 432 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $89.79 | 38.6% | 5 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $29.56 | 12.7% | 1 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $22.95 | 9.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.68 | 8.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.26 | 8.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.19 | 7.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.07 | 7.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.82 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $232.32 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $72.60 | 4 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $35.47 | 2 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $35.47 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $29.56 | 1 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
432 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 958 | 202 |
| Amlodipine Besylate | Amlodipine Besylate | 633 | 149 |
| Levothyroxine Sodium | Levothyroxine Sodium | 525 | 93 |
| Omeprazole | Omeprazole | 503 | 108 |
| Metformin Hcl | Metformin Hcl | 474 | 91 |
| Furosemide | Furosemide | 441 | 92 |
| Gabapentin | Gabapentin | 440 | 102 |
| Eliquis | Apixaban | 432 | 45 |
| Potassium Chloride | Potassium Chloride | 397 | 83 |
| Lisinopril | Lisinopril | 376 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 366 | 73 |
| Losartan Potassium | Losartan Potassium | 360 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 325 | 61 |
| Carvedilol | Carvedilol | 261 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 260 | 54 |
| Trulicity | Dulaglutide | 250 | 46 |
| Memantine Hcl | Memantine Hcl | 248 | 43 |
| Donepezil Hcl | Donepezil Hcl | 240 | 42 |
| Jardiance | Empagliflozin | 226 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 220 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 219 | 54 |
| Meloxicam | Meloxicam | 219 | 50 |
| Fluoxetine Hcl | Fluoxetine Hcl | 212 | 37 |
| Allopurinol | Allopurinol | 199 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 196 | 36 |
| Trazodone Hcl | Trazodone Hcl | 184 | 44 |
| Sertraline Hcl | Sertraline Hcl | 174 | 33 |
| Divalproex Sodium | Divalproex Sodium | 168 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 153 | 31 |
| Nifedipine Er | Nifedipine | 151 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 142 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 33 |
| Alendronate Sodium | Alendronate Sodium | 141 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 130 | 25 |
| Levetiracetam | Levetiracetam | 128 | 26 |
| Finasteride | Finasteride | 125 | 19 |
| Aripiprazole | Aripiprazole | 121 | 22 |
| Simvastatin | Simvastatin | 117 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 114 | 68 |
| Pregabalin | Pregabalin | 113 | 21 |
| Entresto | Sacubitril/Valsartan | 110 | suppressed |
| Tradjenta | Linagliptin | 108 | 24 |
| Prednisone | Prednisone | 107 | 74 |
| Ibuprofen | Ibuprofen | 106 | 37 |
| Valsartan | Valsartan | 102 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 22 |
| Enalapril Maleate | Enalapril Maleate | 99 | 20 |
| Spironolactone | Spironolactone | 98 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 46 |
| Clonidine Hcl | Clonidine Hcl | 96 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 35 |
| Atenolol | Atenolol | 85 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 85 | 60 |
| Clonazepam | Clonazepam | 83 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 31 |
| Azithromycin | Azithromycin | 80 | 74 |
| Buspirone Hcl | Buspirone Hcl | 79 | 18 |
| Celecoxib | Celecoxib | 77 | 19 |
| Mounjaro | Tirzepatide | 76 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 71 | suppressed |
| Lorazepam | Lorazepam | 71 | 14 |
| Levofloxacin | Levofloxacin | 68 | 51 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | suppressed |
| Xarelto | Rivaroxaban | 68 | 12 |
| Mirtazapine | Mirtazapine | 67 | suppressed |
| Famotidine | Famotidine | 66 | 19 |
| Glimepiride | Glimepiride | 66 | 13 |
| Tramadol Hcl | Tramadol Hcl | 64 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 17 |
| Benztropine Mesylate | Benztropine Mesylate | 60 | 12 |
| Risperidone | Risperidone | 60 | 15 |
| Metformin Hcl Er | Metformin Hcl | 59 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | suppressed |
| Ozempic | Semaglutide | 57 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 55 | suppressed |
| Januvia | Sitagliptin Phosphate | 53 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 51 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 51 | suppressed |
| Vascepa | Icosapent Ethyl | 50 | suppressed |
| Glipizide | Glipizide | 49 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 49 | 13 |
| Baclofen | Baclofen | 47 | suppressed |
| Ezetimibe | Ezetimibe | 47 | suppressed |
| Latanoprost | Latanoprost | 45 | 11 |
| Synthroid | Levothyroxine Sodium | 45 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 44 | suppressed |
| Sucralfate | Sucralfate | 42 | suppressed |
| Linzess | Linaclotide | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Colchicine | Colchicine | 40 | 14 |
| Lactulose | Lactulose | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Rexulti | Brexpiprazole | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 23 |
| Ramipril | Ramipril | 37 | suppressed |
| Novolin R | Insulin Regular, Human | 36 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | suppressed |
| Nystatin | Nystatin | 35 | 21 |
| Fluconazole | Fluconazole | 33 | 24 |
| Haloperidol | Haloperidol | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 14 |
| Nystop | Nystatin | 32 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 17 |
| Bumetanide | Bumetanide | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 31 | 15 |
| Ondansetron Odt | Ondansetron | 31 | 22 |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 30 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Risperidone Er | Risperidone Microspheres | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 24 |
| Austedo | Deutetrabenazine | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 25 | suppressed |
| Ibu | Ibuprofen | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 23 |
| Methenamine Hippurate | Methenamine Hippurate | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 20 |
| Ofloxacin | Ofloxacin | 24 | 24 |
| Risperdal Consta | Risperidone Microspheres | 24 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 21 |
| Estradiol | Estradiol | 22 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Novolog | Insulin Aspart | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 17 |
| Brimonidine Tartrate | Brimonidine Tartrate | 21 | suppressed |
| Insulin Lispro | Insulin Lispro | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Letrozole | Letrozole | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Kerendia | Finerenone | 17 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Levemir | Insulin Detemir | 17 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 15 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Auryxia | Ferric Citrate | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 14 |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Renvela | Sevelamer Carbonate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Klor-Con | Potassium Chloride | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Insulin Aspart | Insulin Aspart | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Trandolapril | Trandolapril | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $232.32 · 12 records | ABBVIE INC. | AVYCAZ, Auvelity, BREZTRI, DALVANCE, EMBLAVEO, INGREZZA, NURTEC ODT, OTEZLA, Omnipod, REPATHA, TEFLARO, UBRELVY, VRAYLAR, ZAVZPRET, bio-ConneKt | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error